An FcRn-targeted mucosal vaccine against SARS-CoV-2 infection and transmission

Mostrar otras versiones (1)

SARS-CoV-2 and its variants cause COVID-19, which is primarily transmitted through droplets and airborne aerosols. To prevent viral infection and reduce viral spread, vaccine strategies must elicit protective immunity in the airways. FcRn transfers IgG across epithelial barriers; we explore FcRn-med...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Weizhong, Wang, Tao, Rajendrakumar, Arunraj M., Acharya, Gyanada, Miao, Zizhen, Varghese, Berin P., Yu, Hailiang, Dhakal, Bibek, LeRoith, Tanya, Tuo, Wenbin, Zhu, Xiaoping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709799/
https://www.ncbi.nlm.nih.gov/pubmed/36451890
http://dx.doi.org/10.1101/2022.11.23.517678

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709799/
https://www.ncbi.nlm.nih.gov/pubmed/36451890
http://dx.doi.org/10.1101/2022.11.23.517678

Ejemplares similares